R
Rainer Puhr
Researcher at University of New South Wales
Publications - 12
Citations - 365
Rainer Puhr is an academic researcher from University of New South Wales. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 4 publications receiving 185 citations. Previous affiliations of Rainer Puhr include Medical University of Vienna.
Papers
More filters
Journal ArticleDOI
Firth's logistic regression with rare events: accurate effect estimates and predictions?
TL;DR: Two simple modifications of Firth's logistic regression resulting in unbiased predicted probabilities are proposed and one introduces some bias, but this is compensated by a decrease in the mean squared error.
Journal ArticleDOI
Bias‐reduced and separation‐proof conditional logistic regression with small or sparse data sets
Georg Heinze,Rainer Puhr +1 more
TL;DR: CFL is proposed as an attractive solution to the stratified analysis of binary data, irrespective of the occurrence of monotone likelihood, and confidence intervals and tests based on the penalized conditional likelihood had close-to-nominal coverage rates and yielded highest power among all methods compared, respectively.
Journal ArticleDOI
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
Rupert Bartsch,Anna S. Berghoff,Julia Furtner,Maximilian Marhold,Elisabeth Bergen,Sophie Roider-Schur,Angelika M. Starzer,H. Forstner,B. Rottenmanner,Karin Dieckmann,Zsuzsanna Bago-Horvath,Helmuth Haslacher,Georg Widhalm,Aysegül Ilhan-Mutlu,Christoph Minichsdorfer,Thorsten Fuereder,Thomas Szekeres,Leopold Oehler,Birgit Gruenberger,Christian F. Singer,Ansgar Weltermann,Rainer Puhr,Matthias Preusser +22 more
TL;DR: The TUXEDO-1 trial as discussed by the authors showed that trastuzumab deruxtecan showed a high intracranial response rate in patients with active brain metastases from HER2-positive breast cancer and should be considered as a treatment option in this setting.
165MO Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial
Rupert Bartsch,Anna S. Berghoff,Julia Furtner,Maximilian Marhold,Elisabeth Bergen,Sophie Roider-Schur,Angelika M. Starzer,H. Forstner,B. Rottenmanner,Karin Dieckmann,Zuszanna Bago-Horvath,Georg Widhalm,Ayseguel Ilhan-Mutlu,Christoph Minichsdorfer,Thorsten Fuereder,Cf. Singer,Ansgar Weltermann,Rainer Puhr,Mattheus Preusser +18 more
Journal ArticleDOI
Lack of impact of ABO blood group or corresponding isoantibodies on the immune response after rabies vaccination.
Christoph Buchta,Günther F. Körmöczi,Georg Heinze,Rainer Puhr,Marion Kompatscher,Gerhard Jüngling,Jana List,Maria Macher,P. Höcker,Thomas Watkins-Riedel,Markus Dettke +10 more
TL;DR: Demand for rabies hyperimmunoglobulin has increased recently, requiring optimization of vaccination schemes for immunized plasma donors, and any correlation of the immune response with blood group or isoantibody levels was not found.